A coronavirus vaccine being developed by Oxford University showed positive results in early trials, triggering an immune response, researchers said Monday.
“The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial programme to confirm this,” Andrew Pollard, a professor at Oxford working on the trial, said in a statement.
The researchers published results in the journal The Lancet on Monday, showing the potential vaccine triggered responses in both parts of the immune system, increasing antibody levels and T-cell levels.
“While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,” said Mene Pangalos, executive vice president at AstraZeneca, the pharmaceutical company working with Oxford to manufacture the vaccine.
The results released Monday are from Phase I/II trials. A larger, Phase III trial will be needed to fully show that the vaccine is effective.
Read more at The Hill